Are Patients at Risk for Recurrent Disease Activity After Switching From Remicade^® to Remsima^®? An Observational Study.

ABSTRACT: Background: Since the late '90s, infliximab (Remicade^®) is being used successfully to treat patients with several non-infectious immune mediated inflammatory diseases (IMIDs). In recent years, infliximab biosimilars, including Remsima^® were introduced in clinical practice. Aim: To investigate the interchangeability of Remicade^® (originator infliximab) and its biosimilar Remsima^® in patients with rare immune-mediated inflammatory diseases (IMIDs). Methods: This two-phased prospective open label observational study was designed to monitor the transition from Remicade^® to Remsima^® in patients with rare IMIDs. All included patients were followed during the first 2 years. The primary endpoint was the demonstr

SUBMITTER: Xue L 

PROVIDER: S-EPMC7424016 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature